Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
A research letter published in JAMA Psychiatry reports that reduced grip strength may represent a transdiagnostic marker across schizophrenia and depression, including remitted depression.
A research letter published in JAMA Psychiatry reports that reduced grip strength may represent a transdiagnostic marker across schizophrenia and depression, including remitted depression.
Experts highlighted the clinical and neurobiological overlap between sleep disturbances and psychiatric conditions at the 2026 NP Institute in Nashville.
Experts highlighted the clinical and neurobiological overlap between sleep disturbances and psychiatric conditions at the 2026 NP Institute in Nashville.
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
